Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Now measurable in plasma: eMTBR-Tau

29

Sep 2026

Now measurable in plasma: eMTBR-Tau

Tau tangles are closely linked to Alzheimer’s disease progression. But the tau species associated with these aggregates are present at exceptionally low levels in blood, making them difficult to measure.

From wild rice to tarwi, researchers are exploring the health potential of Indigenous foods

28

Sep 2026

From wild rice to tarwi, researchers are exploring the health potential of Indigenous foods

A conference paper reviewed North American and Andean Indigenous foods, including Three Sisters crops, wild rice, native berries, tarwi, quinoa, and amaranth, and described their nutrients and bioactive compounds. Evidence for health effects remains limited for many of these foods, and the authors call for research developed with Indigenous communities that also supports traditional knowledge and food sovereignty.

From espresso to filter coffee, brewing may shape what reaches your gut

28

Sep 2026

From espresso to filter coffee, brewing may shape what reaches your gut

A focused narrative review traces how caffeine, chlorogenic acids, and coffee fibers move through the gut and interact with microbes. The authors identify plausible links between the microbiome and liver health, but human studies have not shown that microbiome changes cause coffee’s reported metabolic benefits.

An approved Ebola antibody may miss its mark against Bundibugyo virus

28

Sep 2026

An approved Ebola antibody may miss its mark against Bundibugyo virus

Researchers analyzed 44 Bundibugyo virus genomes and modeled how approved and experimental Ebola antibodies might bind the virus’s glycoprotein. The models predicted disrupted binding for Ebanga, conserved targets for MBP134, and different binding behavior for the complete Inmazeb cocktail than for two of its antibodies alone; laboratory tests are needed to determine whether these findings translate into treatment benefit.

Blood markers linked to healthy eating may reflect more than food choices

28

Sep 2026

Blood markers linked to healthy eating may reflect more than food choices

Researchers analyzed dietary data from 204,938 UK Biobank participants and identified blood protein and metabolite profiles associated with adherence to the EAT-Lancet diet. These profiles showed stronger links to several health outcomes and modeled life expectancy than the diet score, but the observational study cannot establish that the diet caused those differences.

Shoppers valued healthier, greener foods, but still chose meat

28

Sep 2026

Shoppers valued healthier, greener foods, but still chose meat

In a discrete choice experiment involving 272 Dutch adults, researchers examined how people valued meat, meat replacers, and legumes across pasta and traditional potatoes-meat-vegetables meals. Health and sustainability labels ranked highly, but participants still tended to favor meat when measured product attributes were held constant, with only modest differences across meal settings.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.